COVID-2019–2020–2021: Systematic review and meta-analysis
Autor: | Heena Tiwari, SGanesh Kumar Reddy, Maanini Mantena, SameerKrishna Prasad Garlapati, BPrasanth Manohar, Harpreet Singh, KaranSingh Bajwa |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Pediatrics
medicine.medical_specialty clinical features Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Scopus Bioengineering Disease Review Article systemic review outcomes General Biochemistry Genetics and Molecular Biology Pharmacy and materia medica Pandemic medicine General Pharmacology Toxicology and Pharmaceutics QD71-142 business.industry Mean age medicine.disease meta-analysis RS1-441 Pneumonia covid-19 Meta-analysis business Analytical chemistry |
Zdroj: | Journal of Pharmacy and Bioallied Sciences, Vol 13, Iss 6, Pp 921-926 (2021) Journal of Pharmacy & Bioallied Sciences |
ISSN: | 0975-7406 |
Popis: | Introduction: The world has faced the pandemic of COVID-19 in March 2020 and still it continues to affect in 2021. There is a great variation about the course of the disease and its features. Hence, in the present systemic review, we intend to determine the pooled estimations in the clinical features and prognosis along with the subgroups based on the severity of the disease in various regions of the world. Materials and Methods: Online data were collected from the search engines of EBSCO, PubMed, Google Scholar, and Scopus. The searched terms were COVID 19, CORONA, SARS-CoV-2, clinical features, Wuhan, etc. The study articles were collected that from January 2020 to February 2021. Based on the PRISMA guidelines, a meta-analysis was performed. Results: A total of 5067 articles were selected, of which 176 were finalized for the study. There were a total of 11 countries that were included, with a total of 2½ lakh participants. Mean age was 47.5 years. Around 22.5% had comorbidities. The mortality was 5.5%. We observed a strong association between the medical condition of the patient and the severity of the infection. In severe cases, the most common symptoms were respiratory and gastrointestinal. The mortality was registered in those with pneumonia and end-organ failure. Conclusion: It can be concluded from this meta-analysis that in a fourth of the positive patients, the disease was severe. In nearly 6% of the COVID-19 patients, mortality was seen. Patients with comorbidities and the severe form of the disease should be closely monitored. |
Databáze: | OpenAIRE |
Externí odkaz: |